Compounds > 9-(3-fluoro-2-phosphonylmethoxypropyl)adenine
Page last updated: 2024-12-07

9-(3-fluoro-2-phosphonylmethoxypropyl)adenine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

9-(3-fluoro-2-phosphonylmethoxypropyl)adenine: highly selective antiretroviral agent in vivo & vitro; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID122652
SCHEMBL ID384145
MeSH IDM0189243

Synonyms (17)

Synonym
phosphonic acid, [[2-(6-amino-9h-purin-9-yl)-1-(fluoromethyl)ethoxy]methyl]-, (1)-
135295-27-1
[1-[(6-aminopurin-9-yl)methyl]-2-fluoro-ethoxy]methylphosphonic acid
(rs)-9-[(3-fluoro-2-(phosphonylmethoxy)propyl]adenine
fpmpa
[1-(6-aminopurin-9-yl)-3-fluoropropan-2-yl]oxymethylphosphonic acid
phosphonic acid, ((2-(6-amino-9h-purin-9-yl)-1-(fluoromethyl)ethoxy)methyl)-, (+-)-
3-fpmpa
9-(3-fluoro-2-phosphonylmethoxypropyl)adenine
SCHEMBL384145
[1-[[(9r)-6-aminopurin-9-yl]methyl]-2-fluoro-ethoxy]methylphosphonic acid
[1-[[(9s)-6-aminopurin-9-yl]methyl]-2-fluoro-ethoxy]methylphosphonic acid
({[1-(6-amino-9h-purin-9-yl)-3-fluoropropan-2-yl]oxy}methyl)phosphonic acid
DTXSID50928947
CS-0645958
HY-153005
(2rs)-fpmpa

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Nine cats received PMEA at a dosage of 10 mg/kg body weight, nine cats received FPMPA at a dosage of 25 mg/kg body weight."( [Comparative investigation of the efficacy of two nucleocapsid analogs in FIV infected cats].
Balzarini, J; Erfle, V; Goebel, F; Goldberg, M; Hartmann, K; Kuffer, M; Rolinski, B, 1997)		0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's7 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.15 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (28.57%)5.53%
Reviews2 (28.57%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other3 (42.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
adenine
[no description available]		11.92726-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
cytosine
[no description available]		3.9920aminopyrimidine;
pyrimidine nucleobase;
pyrimidone		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
adefovir
adefovir: inhibitor of African swine fever virus. adefovir(1-) : A organophosphonate oxoanion obtained by removal of a proton from the phosphonate group of adefovir, a nucleoside reverse transcriptase inhibitor. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).. adefovir : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens has been replaced by a 2-(6-amino-9H-purin-9-yl)ethoxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(t-butoxycarbonyloxymethyl) ester (dipivoxil ester) prodrug is used to treat chronic hepatitis B viral infection.		6.79626-aminopurines;
ether;
phosphonic acids		antiviral drug;
DNA synthesis inhibitor;
drug metabolite;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent
cidofovir anhydrous
Cidofovir: An acyclic nucleoside phosphonate that acts as a competitive inhibitor of viral DNA polymerases. It is used in the treatment of RETINITIS caused by CYTOMEGALOVIRUS INFECTIONS and may also be useful for treating HERPESVIRUS INFECTIONS.. cidofovir anhydrous : Cytosine substituted at the 1 position by a 3-hydroxy-2-(phosphonomethoxy)propyl group (S configuration). A nucleoside analogue, it is an injectable antiviral used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients.		3.9920phosphonic acids;
pyrimidone		anti-HIV agent;
antineoplastic agent;
antiviral drug;
photosensitizing agent
9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine
[no description available]		1.9810
1,n(6)-ethenoadenine
1,N(6)-ethenoadenine: biologically active fluorescent derivatives of this cpd potentially valuable in studies concerning interactions between adenine cpds & various enzymes for which they serve as substrates or co-factors; structure		1.9810imidazo[2,1-i]purinemutagen
organophosphonates
hydrogenphosphite : A divalent inorganic anion resulting from the removal of a proton from two of the hydroxy groups of phosphorous acid.		6.9272divalent inorganic anion;
phosphite ion
ConditionIndicatedRelationship StrengthStudiesTrials
B Virus Infection
[description not available]		02.910
Infections, Retroviridae
[description not available]		02.910
Retroviridae Infections
Virus diseases caused by the RETROVIRIDAE.		02.910
AIDS, Feline
[description not available]		04.3422
Mucositis, Oral
[description not available]		03.3811
Stomatitis
INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.		03.3811
Cell Transformation, Neoplastic
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.		01.9710
HIV
Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.		01.9710
Acquired Immune Deficiency Syndrome
[description not available]		02.8910
Acquired Immunodeficiency Syndrome
An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.		02.8910